Dr. Barry Horowitz, M.D.

Medicare patients and services

Medicare patients, 2024

1,043

Services billed

40,874

Patients’ average age

76

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 26 companies reported 177 payments worth $59,942 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Florida →

Industry-funded research

Named as a principal investigator on 24 industry-funded studies in 2025, from 6 companies. The companies reported $1,132,064 in research payments for these studies, mostly to the institutions running them.

• A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity
  Eli Lilly and Company · Active, not recruiting · NCT06859268
• A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
  AbbVie Inc. · Active, not recruiting · NCT06345339
• A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study evaluating the efficacy and long-term safety of tirzepatide once weekly compared to placebo in adults with type 1 diabetes and…
  Eli Lilly and Company
• A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo
  Incyte Corporation
• M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
  AbbVie Inc.
• A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
  Eli Lilly and Company · Completed · NCT06045221
• A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
  Eli Lilly and Company · Active, not recruiting · NCT05556512
• 17 b-hydroxysteroid dehydrogenase type 13 minimization for the treatme
  GlaxoSmithKline, LLC.
• A multicenter randomized, double-blind, placebo-controlled phase 2 stu
  GlaxoSmithKline, LLC.
• A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
  AbbVie Inc.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Endocrinology & Diabetes clinicians in West Palm Beach

• Morolake O. Amole, MD
• Alexis Da Silva, MD
• Maxwell E. Horowitz, DO
• Geetanjali Kale, MBBS
• William Kaye, M.D.
• Kort C. Knudson, MD
• Margaret M. Mccormack, ARNP
• Sharon C. Miller, MD